|Chemotherapy Agents||Incidence (%)||Frequency of Use|
|Cisplatin (Platinol-AQ) (130)||8.5||+++|
|Lenalidomide (Revlimid) (144–149)||3–75⁎||+|
|Thalidomide (Thalomid) (133–143)||1–58⁎||+|
|Histone deacetylase inhibitor|
|Vorinostat (Zolinza) (10,131,132)||4.7–8||+|
|Small molecule tyrosine kinase inhibitors|
|Erlotinib (Tarceva) (10)||3.9–11||+++|
For an explanation of the + symbols, please see Table 1.
↵⁎ The incidence of venous thromboembolism varies widely in the literature for angiogenesis inhibitors depending on the patient's disease status, concomitant use of high- or low-dose dexamethasone, erythropoietin, or other chemotherapeutic agents, and whether or not thromboprophylaxis was employed during the study period. Medication manufacturers and locations: Platinol-AQ, Bristol-Myers Squibb, Princeton, New Jersey; Revlimid and Thalomid, Celgene Corp., Summit, New Jersey; Zolinza, Merck & Co. Inc., Whitehouse Station, New Jersey; Tarceva, OSI Pharmaceuticals Inc., Melville, New York.